Results 41 to 50 of about 50,237 (216)
Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab. [PDF]
PLoS ONE, 2017 The EGFR-specific mAb cetuximab is one of the most effective treatments for oropharyngeal carcinoma, while patient responses to EGFR inhibitors given alone are modest.
Chaonan Sun +6 more
doaj +1 more source
, 2017 Background: Previous studies have shown left-sided colorectal cancer (LCRC) and right-sided colorectal cancer (RCRC) exhibit different molecular and clinicopathological features.
邵幼雲;賴美淑;林宗哲;林育麟;鄭安理;葉坤輝;陳國興 +1 more
core +1 more source
Advanced Science, EarlyView.Nanomaterials offer dual applications in allergy management. For diagnosis, nanomaterials enhance analytical sensitivity and improve detection in specific IgE and functional assays such as the basophil activation test (BAT). For allergen‐specific immunotherapy, nanomaterials enable allergen masking and controlled release, and effectively modulate the ...
Madiha Habib +8 more
wiley +1 more source
Cancer Medicine, 2019 Purpose Combination of biological therapy and chemotherapy improves the survival of patients with metastatic colorectal cancer (mCRC). However, the optimal biological therapy sequence remains unclear.
Hung‐Chih Hsu +7 more
doaj +1 more source
Cetuximab blocked hypoxia-induced EMT.
, 2013 A) Cetuximab blocked hypoxia-induced loss of cell-cell contacts. A431 cells were grown under normoxia, hypoxia or hypoxia+Cetuximab. The cells were fixed, permeabilized and probed with anti-E-cadherin primary antibodies followed by labeled secondary ...
Thirumaran Thanabalu (297734) +3 more
core +1 more source
Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy
Advanced Science, EarlyView.This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier +16 more
wiley +1 more source
Biomolecules, 2019 Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. Cetuximab, a human/mouse chimeric monoclonal antibody, is effective in a limited number of CRC patients because of cetuximab resistance.
Mee Hyun Jeoung +9 more
doaj +1 more source
FIGURE 1 from The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
, 2023 OS by KRAS and treatment arm. A, OS in non-variant patients by radiation level; B, OS in non-variant patients by cetuximab; C, OS in KRAS-variant patients by radiation level; D, OS within KRAS-variant patients by cetuximab.
Chen Hu (15023526) +19 more
core +1 more source
Advanced Science, EarlyView.AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang +21 more
wiley +1 more source
Scientific Reports, 2021 Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is an efficient anti-tumor therapeutic agent that inhibits the activation of EGFR; however, data related to the cellular effects of prolonged cetuximab treatment are limited.
Kohei Okuyama +8 more
doaj +1 more source